{"classes":[{"categories":[{"measurements":[{"comment":"The upper 95% confidence interval was not reached due to Insufficient number of participants with events to reach the threshold according to Kaplan-Meier methodology.","groupId":"OG000","lowerLimit":"18.00","upperLimit":"NA","value":"43.47"},{"comment":"The upper 95% confidence interval was not reached due to Insufficient number of participants with events to reach the threshold according to Kaplan-Meier methodology.","groupId":"OG001","lowerLimit":"2.4","upperLimit":"NA","value":"30.32"},{"comment":"The upper 95% confidence interval was not reached due to Insufficient number of participants with events to reach the threshold according to Kaplan-Meier methodology.","groupId":"OG002","lowerLimit":"7.13","upperLimit":"NA","value":"26.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"The duration of CR was only evaluated in participants with BOR of CR and was defined as the time from first documentation of CR (the date of first negative FDG-PET scan or the date of first documentation of no disease involvement in the bone marrow (if required), whichever occurred later) to the date of initial objectively documented progression (Any new lesion or increase by \\>=50% of previously involved sites from nadir) as determined using the 2007 IWG criteria or death due to any cause, whichever occurred first. Censoring was applied as per DOR definition.\n\nComputed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG000","title":"Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG001","title":"Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG002","title":"Cohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant"}],"paramType":"MEDIAN","populationDescription":"All treated Cohort A, B and C participants who had a BOR of CR.","reportingStatus":"POSTED","timeFrame":"From first dose to the date of initial objectively documented progression or the date of subsequent therapy, or death whichever occurred first (up to approximately 100 months)","title":"Duration of Complete Remission (CR) Based on IRRC Assessments for Cohorts A, B, and C","type":"SECONDARY","unitOfMeasure":"Months"}